Long-Term Results of Transscleral Diode Laser Cyclophotocoagulation in Glaucoma: A Real-Life Study

Author:

Sari Cem,Alagoz Nese,Omeroglu Asena,Cakir Ihsan,Pasaoglu Isil,Altan Cigdem,Yasar Tekin

Abstract

Précis: Transscleral diode laser cyclophotocoagulation is effective and safe in a large population and different types of glaucoma, but is least effective in NVG group. Purpose: We aimed to investigate the clinical outcomes of transscleral diode laser cyclophotocoagulation (TDLC) in a large cohort of patients with different types of refractory glaucoma. Patients and Methods: Using patient charts, we retrospectively analyzed the success and complications of TDLC performed on eyes categorized in 6 groups: primary glaucoma (116 eyes), trauma (41 eyes), neovascular glaucoma (NVG, 84 eyes), post-vitreoretinal surgery (post-VRS, 79 eyes), penetrating keratoplasty (PK, 47 eyes), and miscellaneous (40 eyes). Failure was defined as intraocular pressure (IOP) >22 mmHg or <5 mmHg, the need for further glaucoma surgery, and the loss of light perception during follow-up. Results: Overall, the mean follow-up time was 33.4±17.4 months, the mean total energy delivered was 109.2±56.5 J, and the mean IOP reduction rate was 41.8%. Total energy delivered and IOP reduction rates were similar between the groups (all P >0.05). The probability of success at 36 months was 71.5%, 70.7%, 55.9%, 77.2%, 72.3%, and 72.5% in the primary glaucoma, trauma, NVG, post-VRS, PK, and miscellaneous groups, respectively. The NVG group showed a significantly lower success rate (P=0.009) than the other groups. Significant complications consisted of phthisis bulbi in 1 eye (0.2%) in the NVG group and chronic hypotony in 7 eyes (1.7%) in the NVG (3 eyes), trauma (2 eyes), post-VRS (1 eye), and primary glaucoma (1 eye) groups. Conclusions: Although TDLC was found to be a safe, effective method in the long term, it was least effective in eyes with NVG.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3